<DOC>
	<DOCNO>NCT01356992</DOCNO>
	<brief_summary>This non-inferiority study aim compare Versa® reference enoxaparin ( Clexane® , Sanofi-Aventis ) patient high-risk unstable angina NSTEMI . The main justification search scientific evidence prove Versa® effectiveness new therapeutic indication , since product potential reducing cost , effectiveness safety comparable reference drug .</brief_summary>
	<brief_title>Patients With High-risk Acute Coronary Syndrome Without ST-segment Elevation</brief_title>
	<detailed_description>To include study , eligible patient must meet criterion : IC signature ; The research subject must agree follow instruction perform procedure study visit ; Men woman age 18 age 75 ; History angina rest minimum duration 20 minute last 24 hour begin least 10 day . Patient Randomization 6 hour arrival emergency sector . Evidence NSTEMI unstable angina due one follow criterion : 1 . Dynamic alteration T-wave ( ST-segment depression elevation &gt; 1 mm , and/or T-wave inversion solve least partially symptom relieve ) 2 . Unevenly ST-segment ( depression elevation ) transitional way continuous derivation ( V1+V2 V3+V4 V5+V6 D1+AVL D2+D3+AVF ) 3 . Biochemical alteration myocardial necrosis marker ( CKMB mass , troponin T I CPK ) , appearance enzymatic curve , characterize myocardial injury 5 . Pulmonary Edema ; 6 . Angina associate murmur mitral regurgitation ; 7 . Angina heart sound cardiac auscultation throe ; 8 . Angina hypotension ; The patient meet anyone criterion eligible study : 12-derivation-ECG persistent ST-segment elevation ; Diagnosis angina secondary cause ( e.g. , anemia , fever , hypovolemia , dehydration , use cocaine ) ; Use non-fractionated heparin low-molecular weight heparin prior 48 randomization ; Concomitant diseases , severe renal failure ( creatinine clearance low 30ml/min . ) hepatic , significant comorbidities investigator judgment ; Recent hemorrhagic cerebrovascular accident ( last 12 month ) ; Patient schedule cardiac surgery myocardial revascularization ; Use drug , alcohol abuse ; Pregnancy lactation ; Recent neurosurgery ophthalmic surgery ( last 3 month ) ; History diagnosis coagulopathy ; Medical record containing allergy , hypersensibility intolerance drug component use study , judge clinically significant main investigator 's opinion ; Recent participation ( last 12 month ) clinical study .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Angina , Unstable</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Enoxaparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>ICF signature ; The research subject must agree follow instruction perform procedure study visit ; Men woman age 18 age 75 ; History angina rest minimum duration 20 minute last 24 hour begin least 10 day . Patient Randomization 6 hour arrival emergency sector . Evidence NSTEMI unstable angina due one follow criterion : 1 . Dynamic alteration Twave ( STsegment depression elevation &gt; 1 mm , and/or Twave inversion solve least partially symptom relieve ) 2 . Unevenly STsegment ( depression elevation ) transitional way continuous derivation ( V1+V2 V3+V4 V5+V6 D1+AVL D2+D3+AVF ) 3 . Biochemical alteration myocardial necrosis marker ( CKMB mass , troponin T I CPK ) , appearance enzymatic curve , characterize myocardial injury 5 . Pulmonary Edema ; 6 . Angina associate murmur mitral regurgitation ; 7 . Angina heart sound cardiac auscultation throe ; 8 . Angina hypotension ; 12derivationECG persistent STsegment elevation ; Diagnosis angina secondary cause ( e.g. , anemia , fever , hypovolemia , dehydration , use cocaine ) ; Use nonfractionated heparin lowmolecular weight heparin prior 48 randomization ; Concomitant diseases , severe renal failure ( creatinine clearance low 30ml/min . ) hepatic , significant comorbidities investigator judgment ; Recent hemorrhagic cerebrovascular accident ( last 12 month ) ; Patient schedule cardiac surgery myocardial revascularization ; Use drug , alcohol abuse ; Pregnancy lactation ; Recent neurosurgery ophthalmic surgery ( last 3 month ) ; History diagnosis coagulopathy ; Medical record containing allergy , hypersensibility intolerance drug component use study , judge clinically significant main investigator 's opinion ; Recent participation ( last 12 month ) clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>non-inferiority phase III study</keyword>
	<keyword>Low-Molecular Weight Heparin</keyword>
	<keyword>Versa® ( enoxaparin - Eurofarma )</keyword>
	<keyword>Clexane® ( enoxaparin - Sanofi-Aventis )</keyword>
	<keyword>Acute coronary syndrome without ST-segment elevation</keyword>
</DOC>